Is Vertex Pharmaceuticals (VRTX) overvalued or fairly valued?

MarketChacha shows Vertex Pharmaceuticals's valuation in context — a trailing P/E of about 33.1, a forward P/E of about 25.2, a price-to-book of about 6.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Vertex Pharmaceuticals's reported profit turn into cash?

Over 3 years, about 95% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement. MarketChacha computes this cash-conversion check (0.95×) from reported figures — education, not a rating.

What is Vertex Pharmaceuticals's revenue?

Vertex Pharmaceuticals reported revenue of $12.0B for FY2025, with net profit of $4.0B, per official filings.

What is the share price of Vertex Pharmaceuticals (VRTX)?

Vertex Pharmaceuticals last traded at $546.12 (-2.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Vertex Pharmaceuticals

VRTX · NASDAQ · Healthcare · United States

Snapshot

TickerVRTX

ExchangeNASDAQ

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees6,400

HeadquartersBoston, United States

Websitewww.vrtx.com

Filings tracked14

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Who owns it

Insiders0.2%
Institutions98.1%
Public & other1.7%

2,435 institutional holders

Ownership breakdown from public market data.

Top holders

Capital World Investors10.29%
Blackrock Inc.9.50%
Capital Research Global Investors7.68%
Vanguard Capital Management LLC6.53%
State Street Corporation4.68%
Invesco Ltd.3.17%
JPMORGAN CHASE & CO2.57%
Geode Capital Management, LLC2.37%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years, about 95% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement.

Cash conversion0.95×

Over 3 years, about 95% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement.

Net margin trend36.7% → 32.9%

Margin has compressed by about 3.7 points over the period — profitability is trending down.

Return on equity21.2%

Latest ROE of 21.2% — capital is generating a healthy return.

Growth qualityrev 10% · PAT 5%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $3.5B · EPS 4.88

Est. earnings growth -2.9%

Next fiscal year

Rev $14.6B · EPS 21.77

Est. earnings growth +30.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$12.0B

Net margin

32.9%

ROE

21.2%

Revenue CAGR (2y)

+10.3%

Profit CAGR (2y)

+4.5%

EPS (FY2025)

15.32

Net profit (FY2025)

$4.0B

Ask MarketChacha about VRTX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$12.0B	$4.0B	15.32	32.9%	21.2%
FY2024	$11.0B	$-535.6M	-2.08	-4.9%	-3.3%
FY2023	$9.9B	$3.6B	13.89	36.7%	20.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$3.3B	$1.1B	4.31	33.0%
2026Q1	$3.0B	$1.0B	4.02	34.5%
2025Q3	$3.1B	$1.1B	4.20	35.2%
2025Q2	$3.0B	$1.0B	3.99	34.8%
2025Q1	$2.8B	$646.3M	2.49	23.3%
2024Q3	$2.8B	$1.0B	4.01	37.7%
2024Q2	$2.6B	$-3.6B	-13.92	-135.8%
2024Q1	$2.7B	$1.1B	4.21	40.9%
2023Q3	$2.5B	$1.0B	3.97	41.7%
2023Q2	$2.5B	$915.7M	3.52	36.7%
2023Q1	$2.4B	$699.8M	2.69	29.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/4/2026
8-K — Results of operations, Exhibits
SEC8/3/2026material
8-K — Material agreement, Reg FD disclosure, Other events, Exhibits
SEC7/7/2026material
8-K — Executive/director change, Shareholder vote results
SEC5/13/2026material
10-Q filing
SEC5/5/2026
8-K — Results of operations, Exhibits
SEC5/4/2026material
8-K — Executive/director change
SEC4/29/2026material
8-K — Other events
SEC3/31/2026material
10-K filing
SEC2/13/2026
8-K — Results of operations, Exhibits
SEC2/12/2026material

2025

10-Q filing
SEC11/4/2025
8-K — Results of operations, Exhibits
SEC11/3/2025material
10-Q filing
SEC8/5/2025
8-K — Results of operations, Executive/director change, Exhibits
SEC8/4/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.